Michael King Schultz
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$8.3MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $8.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | STTR Phase II Antibody-based prertargeted alpha particle therapy for ovarian cancer | $1.0M | VIEWPOINT MOLECULAR TARGETING, INC. |
| Jun 5, 2024 | NIH | STTR Phase II Antibody-based prertargeted alpha particle therapy for ovarian cancer | $392K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Jul 28, 2023 | NIH | SBIR Phase II Image-guided dosimetry-based alpha particle therapy for neuroblastoma. | $961K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Jun 28, 2023 | NIH | SBIR Phase II Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma | $948K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Jun 29, 2022 | NIH | SBIR Phase II Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma | $977K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Aug 3, 2021 | NIH | SBIR Phase II GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma. | $1000K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Aug 3, 2021 | NIH | SBIR Phase II Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors. | $999K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Sep 15, 2020 | NIH | SBIR Phase II Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors. | $998K | VIEWPOINT MOLECULAR TARGETING, INC. |
| Sep 7, 2020 | NIH | SBIR Phase II GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma. | $1000K | VIEWPOINT MOLECULAR TARGETING, INC. |
Peer ranks
Federal funding#104
Awards as PI#151
Patents#273
Companies
- VIEWPOINT MOLECULAR TARGETING, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.